TCGA-66-2773-01A-01R-1201-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.550
- MYC_TARGETS_V2+0.500
- MTORC1_SIGNALING+0.420
- E2F_TARGETS+0.380
- G2M_CHECKPOINT+0.380
- MYC_TARGETS_V1+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.350
- IL6_JAK_STAT3_SIGNALING+0.300
- PI3K_AKT_MTOR_SIGNALING+0.280
- MITOTIC_SPINDLE+0.270
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.440
- COAGULATION-0.120
- HEDGEHOG_SIGNALING-0.120
- KRAS_SIGNALING_UP-0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.090
- CHOLESTEROL_HOMEOSTASIS-0.060
- KRAS_SIGNALING_DN-0.050
- FATTY_ACID_METABOLISM-0.030
- MYOGENESIS-0.030
- SPERMATOGENESIS-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900008 | — | — | 0.801 |
| 2 | MNG485 | — | — | 0.794 |
| 3 | TCGA-52-7812-01A-11R-2125-07 | — | cohortA1 | 0.790 |
| 4 | SRR6013600 | — | cohortA1 | 0.787 |
| 5 | SRR1313147 | — | E | 0.784 |
| 6 | 33800B09-6DCC-4BE8-891C-5F34ADAC65B3 | — | — | 0.782 |
| 7 | TCGA-66-2759-01A-01R-0851-07 | — | cohortSQ2 | 0.781 |
| 8 | 20130321.TNBC | — | C | 0.779 |
| 9 | MDT-AP-0154 | Med | Medulloblastoma | 0.777 |
| 10 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |